Advanced Ovarian Cancer Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

The advanced ovarian cancer market was valued at USD 1.48 Billion in 2024 , driven by the increasing prevalence of ovarian cancer, new therapies, and expanded treatment options among 8 major markets. It is expected to grow at a CAGR of 2.20% during the forecast period of 2025-2034, and attain a market value of USD 1.84 Billion by 2034 .

Advanced Ovarian Cancer Market Overview

Advanced ovarian cancer occurs when cancerous growths in the ovaries have extended beyond the pelvic area. It is challenging to identify in the early stages because of its typical symptoms like bloating, pelvic or abdominal pain, eating problems, frequent urination, fatigue, constipation, back pain, weight loss, shortness of breath, and ascites. The main cause of advanced ovarian cancer is uncontrolled cell division in ovarian tissues. There is a higher risk of genetic mutations such as BRCA1 and BRCA2. Various factors that can impact the cancer are age, family history of cancer, hormonal factors, and lifestyle habits have an impact. Late detection is frequent because there are no initial signs, causing cancer to spread outside the ovaries.

The typical approach for the treatment involves a combination of surgery, chemotherapy, and targeted therapies. The surgery helps to eliminate as many cancer cells as possible. Chemotherapy is commonly employed to reduce tumor size, frequently utilizing platinum-based medications such as carboplatin and paclitaxel. Specialized treatments, such as Olaparib and a PARP inhibitor, are becoming more common for cancers with BRCA mutations. Hormone treatments are utilized for certain forms of ovarian cancer. Personalized treatment methods based on progress in precision medicine are enhancing results for individuals with late-stage ovarian cancer.

Advanced Ovarian Cancer Market Growth Drivers

Rising Incidence of Ovarian Cancer Spurs Market Growth

The market growth is fueled by the rising prevalence of ovarian cancer, particularly in elderly populations in developed nations such as the United States, Europe, and Japan. According to the American Cancer Society, about 19,680 women will be diagnosed with ovarian cancer while 12,740 women are likely to die with the condition in the United States in 2024. Factors such as lifestyle choices, genetic tendencies, and delayed childbirth are all playing a role in the increasing incidence of advanced ovarian cancer among women aged 50 and above.

Government Support and Fundings to Support Advanced Ovarian Cancer Market Demand

Government support is essential for the advancement of research, treatment, and care for advanced ovarian cancer. Several nations have established funding initiatives to assist in research for innovative treatments, early identification strategies, and services for patient assistance. The U.S. government, particularly via the NCI is concentrating on pioneering research in targeted therapies and immunotherapies. European institutions like Horizon Europe also provide financial support for ovarian cancer research to improve survival rates and treatment efficiency. In 2024, OCRA introduced the Health Equity Research Grant (HEG) sponsored by GSK. It aims to address healthcare disparities in marginalized communities through research on ovarian and gynecologic cancers. Recipients are promised to receive USD 100,000 per year for two years, increasing up to USD 200,000 for conducting their studies at the institution.

Advanced Ovarian Cancer Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Increasing Use of Immunotherapy

Utilizing the immune system to fight cancer cells is transforming the treatment landscape of the disease. Pembrolizumab, a type of checkpoint inhibitor, focuses on proteins that impede immune cell attack on tumors. Clinical trials are investigating the potential of combining checkpoint inhibitors with additional treatments to increase response rates. Personalized cancer vaccines are being designed to enhance the immune response and achieve better results in the treatment of ovarian cancer.

Rising Awareness and Screening Programs to Boost Advanced Ovarian Cancer Market Value

Awareness and screening initiatives play a vital role in the early detection of ovarian cancer, contributing to the growth of the market. Governments and health organizations are conducting educational campaigns regarding risks, symptoms, and genetic testing for BRCA mutations. These initiatives result in quicker identification and increased survival rates in late-stage scenarios. Genetic counselling and support organizations play a crucial role in connecting with a larger number of women.

Advances in Targeted Therapies to Impact Advanced Ovarian Cancer Market Size

Targeted treatments are changing the way advanced ovarian cancer is treated. These treatments target molecular alterations in cancer cells, lessening side effects in contrast to standard chemotherapy. PARP inhibitors such as olaparib and niraparib are successful in targeting BRCA1 and BRCA2 mutations, causing a disruption in DNA repair in cancer cells, and ultimately resulting in their destruction. These treatments enhance the duration of time before the disease progresses and are commonly used in conjunction with chemotherapy. Additionally, Bevacizumab, an angiogenesis inhibitor, works by focusing on blood vessels to reduce the growth of tumors.

Emphasis on Minimally Invasive Surgery

Minimally invasive surgery is becoming more popular for the treatment of advanced ovarian cancer because of its advantages such as shorter recovery times, less time in the hospital, and lower risk of complications. Laparoscopic and robotic-assisted surgeries provide accurate tumor removal while causing minimal harm to healthy tissue, particularly for debulking operations. Sophisticated surgical advancements and education in less invasive procedures are broadening treatment choices, and enhancing patient results and quality of life.

Advanced Ovarian Cancer Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Treatment Type:

• Chemotherapy
• Immunotherapy
• Surgery
• Radiation Therapy
• Targeted Drug Therapy
• Others

Market Breakup by Cancer Type:

• Epithelial Tumor
• Germ Cell Tumor
• Stromal Cell Tumor
• Others

Market Breakup by Route of Administration:

• Oral
• Parenteral
• Others

Market Breakup by End User:

• Hospitals & Clinics
• Diagnostic Centers
• Research Laboratories
• Others

Market Breakup by Region:

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Advanced Ovarian Cancer Market Share

Market Share Based on Cancer Type to Witness Substantial Growth

Based on the cancer type, the market is divided into epithelial tumor, germ cell tumor, stromal cell tumor, and others.

Epithelial tumors among all are expected to lead the market as they make up most ovarian cancer cases, making them the most prevalent type of the disease. This form originates in the cells located on the exterior of the ovary and is typically not detected until later phases, which is why it is linked to advanced ovarian cancer. Because of its common occurrence, most of the research and treatment methods are centered on epithelial ovarian cancer. Treating its late stages is difficult and usually involves using a combination of surgery and systemic treatments.

Germ cell tumors are not as frequent and develop in the reproductive cells of the ovaries, mainly impacting younger females. Surgery and chemotherapy are commonly used to treat these tumors, resulting in effective management if diagnosed early. Stromal cell tumors originate from the connective tissues and hormone-producing cells located in the ovaries. Rarely seen, these tumors have a slow growth rate and are usually detected in earlier stages compared to epithelial tumors.

Advanced Ovarian Cancer Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.

The United States is expected to dominate the market driven by the increase in the elderly population as well as improvements in screening and genetic testing. It is at the forefront of ovarian cancer studies, with a focus on immunotherapies and targeted treatments. Organizations like the NCI offer significant financial backing for research with government support, resulting in enhanced patient outcomes through increased healthcare spending and better treatment access. EU-4 and the United Kingdom are also poised to have a significant market share supported by the increased prevalence of advanced ovarian cancer.

Leading Players in the Advanced Ovarian Cancer Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:

AstraZeneca

AstraZeneca is a multinational pharmaceutical company with headquarters in Cambridge, England. Imfinzi and Lynparza have been recommended for approval in the EU for treating certain patients with endometrial cancer. Lynparza is also approved for treating various types of cancer, including ovarian and breast cancer. The treatments are used for maintenance and advanced stages of the diseases.

F-Hoffmann-La Roche Ltd

Roche, a Swiss multinational healthcare company, operates in pharmaceutical and diagnostic divisions worldwide. Their Avastin monoclonal antibody targets VEGF-A. Initially approved in the US for advanced colorectal cancer, Avastin was the first anti-angiogenic therapy for advanced cancer. It is now approved in Europe for breast, colorectal, lung, kidney, ovarian, and cervical cancers, and in the US for various cancers including colorectal and lung.

AbbVie Inc.

AbbVie is an American pharmaceutical company based in North Chicago, Illinois. The company announced positive topline results in June 2024 from the Phase 2 PICCOLO trial for ELAHERE® in treating platinum-sensitive ovarian cancer patients. ELAHERE® is for adults with folate receptor-alpha positive ovarian cancer who haven't responded well to platinum-based chemotherapy.

GSK plc

GSK plc is a British multinational pharmaceutical company founded in 2000. In July 2023, the U.S. FDA approved the immuno-oncology agent JEMPERLI in combination with chemotherapy for dMMR/MSI-H endometrial cancer. This is a significant development that may drive JEMPERLI royalties.

Other players in the market are Amgen Inc., Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc.

Key Questions Answered in the Advanced Ovarian Cancer Market Report

• What was the advanced ovarian cancer market value in 2024?
• What is the advanced ovarian cancer market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment type?
• What is market segmentation based on cancer type?
• What are the major factors aiding the advanced ovarian cancer market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the major drivers, opportunities, and restraints in the market?
• What are the major trends influencing the market?
• Which regional market is expected to dominate the market share in the forecast period?
• Which country is likely to experience elevated growth during the forecast period?
• Who are the key players involved in the advanced ovarian cancer market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

More Insights on

Advanced Ovarian Cancer Drug Pipeline Analysis

Advanced Recurrent Ovarian Cancer Drug Pipeline Analysis